Results 41 to 50 of about 137,029 (384)
Persistent clinical efficacy and safety of anti-tumour necrosis factor \textgreeka therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response [PDF]
, 2008 Background: There is insufficient evidence for the long-term efficacy and safety of anti-tumour necrosis factor therapy in patients with ankylosing spondylitis (AS).
Alten, R. +11 more
core +1 more source
Infliximab in ulcerative colitis
Biologics: Targets & Therapy, 2008 Infliximab, a monoclonal anti-TNF-alpha antibody, is commonly used for treatment of moderate to severe Crohn's disease (CD). Its role in the treatment for ulcerative colitis (UC) remains controversial. We review the role of TNF-alpha in the pathogenesis of UC and describe the randomized, double-blind, placebo-controlled trials and systematic reviews ...
Avi Levin, Oren Shibolet
openaire +5 more sources
Infliximab maintenance therapy for fistulizing Crohn's disease.
New England Journal of Medicine, 2004 BACKGROUND Infliximab, a monoclonal antibody against tumor necrosis factor, is an effective maintenance therapy for patients with Crohn's disease without fistulas.
B. Sands +17 more
semanticscholar +1 more source
Therapeutic Advances in Gastroenterology, 2015 Objectives: Many patients with Crohn’s disease on infliximab maintenance therapy have recurrent symptoms despite an initial clinical response. Therefore, concomitant therapies have been studied.
Douglas L. Nguyen +5 more
doaj +1 more source
Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
Case Reports in Dermatology, 2017 A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled ...
Yuki Matsuura-Otsuki +3 more
doaj +1 more source
True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin α? [PDF]
, 2004 Background: The combination of methotrexate and the anti-tumour necrosis factor (TNF) antibody infliximab is a very effective treatment for rheumatoid arthritis (RA). However, a proportion of patients are not responsive to this treatment. Inefficacy may
Bingham, S.J. +5 more
core +2 more sources
PLoS Biology, 2019 During rheumatoid arthritis (RA) treatment, long-term injection of antitumor necrosis factor α antibodies (anti-TNFα Abs) may induce on-target toxicities, including severe infections (tuberculosis [TB] or septic arthritis) and malignancy.
Yun-Chi Lu +13 more
doaj +1 more source
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
Respiratory Research, 2022 Background Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis.
Abdullah Sakkat +9 more
doaj +1 more source
Inflammatory Intestinal Diseases, 2021 Background: TNF inhibitors are relatively safe drugs, but asymptomatic infliximab-induced high serum creatine kinase (CK) levels have been reported in >30% of patients with inflammatory bowel disease (IBD).
Manuel Sutter +2 more
doaj +1 more source
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
New England Journal of Medicine, 2003 BACKGROUND Treatment with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, can result in the formation of antibodies against infliximab.
F. Baert +6 more
semanticscholar +1 more source